CLU Antibody

What is CLU protein and why is it significant in research?

Clusterin (CLU) is a highly conserved glycoprotein first isolated from ram rete testes fluid in 1986. It was initially identified as a protein responsible for cell aggregation, hence the name "Clusterin" . Also known as apolipoprotein J, testosterone-repressed prostate message-2 (TPRM-2), sulphated glycoprotein-2 (SGP-2), and complement lysis inhibitor (CLI), CLU is found nearly ubiquitously in tissues and body fluids .

The significance of CLU in research stems from its involvement in multiple cellular processes:

• Apoptosis and cell cycle regulation

• DNA repair mechanisms

• Cellular stress response

• Cancer progression and metastasis

• Chemoresistance in multiple cancer types

CLU has garnered significant research interest due to its overexpression in various cancers, including lung, breast, prostate, gastric, and melanoma, making it a potential biomarker and therapeutic target .

What are the different isoforms of CLU and how do they affect antibody selection?

CLU exists in different isoforms with distinct subcellular localizations and functions:

When selecting antibodies, researchers should consider:

• The specific isoform of interest in their study

• Whether N-terminal or C-terminal targeting is required

• Cross-reactivity between isoforms

• Subcellular localization needs

For example, some studies reported only cytoplasmic CLU staining in lung cancer samples, while others found both nuclear and cytoplasmic staining, highlighting the importance of antibody specificity and validation .

What are the common applications of CLU antibodies in cancer research?

CLU antibodies serve multiple purposes in cancer research:

• Biomarker Detection: CLU is overexpressed in various cancers and is associated with advanced tumor pathological stage, making it a valuable biomarker. Immunohistochemistry using CLU antibodies can help assess prognosis in surgically resected lung adenocarcinoma and other cancers .

• Mechanism Studies: CLU antibodies enable researchers to investigate the role of CLU in:

  • Chemoresistance mechanisms

  • Metastatic pathways, including the EIF3I/Akt/MMP13 signaling pathway

  • Cell survival pathways

• Therapeutic Development: Anti-CLU treatments like Custirsen (OGX-011), a second-generation antisense oligonucleotide that inhibits CLU production, are being developed. CLU antibodies are essential for monitoring the efficacy of such treatments .

• Prognostic Assessment: CLU expression patterns detected by antibodies correlate with patient survival in several cancers, including NSCLC .

How do you optimize CLU antibody dilutions for different experimental applications?

Optimizing CLU antibody dilutions requires systematic titration based on the specific application:

Methodological approach for optimization:

• Gradient Testing: For each application, test a range of dilutions (at least 3-4) spanning the recommended range.

• Sample-Specific Adjustments:

  • For IHC: Optimize antigen retrieval using TE buffer pH 9.0 or citrate buffer pH 6.0 depending on tissue type .

  • For IF: Consider cell-specific fixation protocols; HeLa cells show good results with standard paraformaldehyde fixation .

• Signal-to-Noise Evaluation: Assess both signal intensity and background for each dilution. The optimal dilution provides maximum specific signal with minimal background.

• Validation Controls:

  • Positive controls: Human plasma for WB; human tonsillitis, breast cancer, or liver cancer tissue for IHC .

  • Negative controls: CLU siRNA-treated cells show significant reduction in signal, confirming antibody specificity .

What are the key considerations when using CLU antibodies for detecting different subcellular localizations?

Detecting different subcellular localizations of CLU requires careful consideration of:

• Antibody Epitope Selection:

  • N-terminal specific antibodies (e.g., targeting amino acids 71-99) are essential for distinguishing between secretory and nuclear CLU isoforms .

  • Antibodies targeting the α-chain can detect both nuclear and cytoplasmic isoforms .

• Fixation and Permeabilization:

  • Nuclear CLU detection requires adequate nuclear permeabilization

  • Cytoplasmic CLU may require milder detergents to preserve membrane structures

  • Cross-linking fixatives like paraformaldehyde (4%) are generally preferred

• Confocal Microscopy Techniques:

  • Z-stack imaging is recommended to accurately distinguish nuclear from perinuclear staining

  • Co-staining with nuclear markers (DAPI) and organelle markers (ER, Golgi) helps confirm localization

• Fractionation Controls:

  • Nuclear/cytoplasmic fractionation followed by western blotting provides quantitative validation

  • Compare results from different detection methods to avoid artifacts

Studies on NSCLC have reported conflicting results regarding CLU localization, with some observing exclusively cytoplasmic staining and others finding both nuclear and cytoplasmic patterns. These discrepancies may result from differences in antibody specificity, sample preparation, or genuine biological variation .

How can researchers differentiate between CLU isoforms in experimental settings?

Differentiating between CLU isoforms requires a multi-faceted approach:

• Molecular Weight Discrimination:

  • Full-length secretory CLU: 75-80 kDa heterodimeric glycoprotein

  • Nuclear CLU: ~55 kDa

  • CLU precursor: ~60 kDa

• Strategic Antibody Selection:

  • Use antibodies targeting different domains:

    • N-terminal antibodies can detect nuclear forms

    • Antibodies against the α-chain detect mature forms

    • Antibodies recognizing the uncleaved precursor identify immature forms

• Expression System Controls:

  • Overexpression constructs with tagged specific isoforms

  • siRNA targeting specific isoform transcripts

  • Validation by qRT-PCR for isoform-specific transcripts

• Advanced Experimental Approaches:

  • Immunoprecipitation followed by mass spectrometry

  • Pulse-chase experiments to track CLU processing

  • Proximity ligation assays for interaction partners specific to each isoform

For example, to specifically track CLU processing, researchers can:

• Use N-terminal antibodies like the one described in search result to detect early forms

• Compare with antibodies targeting processed forms to quantify maturation efficiency

• Validate with siRNA knockdown experiments that show selective depletion of specific bands

What are the best practices for validating CLU antibody specificity?

Thorough validation of CLU antibody specificity is crucial for reliable research results:

• Genetic Validation:

  • siRNA/shRNA knockdown: Transfect cells with CLU-specific siRNA and verify signal reduction by immunoblotting and immunofluorescence .

  • CRISPR/Cas9 knockout: Generate CLU knockout cell lines as definitive negative controls.

  • Overexpression: Transfect cells with CLU expression vectors to verify increased signal.

• Multiple Antibody Approach:

  • Use antibodies from different vendors targeting different epitopes

  • Compare staining patterns across techniques (WB, IHC, IF)

  • Ensure consistent molecular weight detection (observed ~37 kDa in some systems, 60-80 kDa in others)

• Peptide Competition Assays:

  • Pre-incubate antibody with the immunizing peptide

  • Observe elimination of specific signals

  • Maintain non-specific background as internal control

• Cross-Species Validation:

  • If the antibody claims cross-reactivity, test across relevant species

  • Compare expression patterns with published transcriptomics data

• Mass Spectrometry Confirmation:

  • Immunoprecipitate with the antibody and confirm CLU identity by mass spectrometry

  • Identify specific peptides corresponding to known CLU sequences

How do sample preparation techniques affect CLU antibody performance in different applications?

Sample preparation significantly impacts CLU antibody performance across different applications:

Key methodological considerations:

• Western Blotting:

  • CLU is glycosylated; consider deglycosylation treatments for more precise molecular weight analysis

  • Include reducing agents for proper chain separation

  • Transfer conditions: use PVDF membranes for better protein retention

• Immunohistochemistry:

  • Overfixation can mask CLU epitopes; optimize fixation time

  • Compare both TE buffer pH 9.0 and citrate buffer pH 6.0 for optimal antigen retrieval

  • Include positive control tissues: human tonsillitis, breast cancer, or liver cancer tissue

• Immunofluorescence:

  • Optimize permeabilization to access different cellular compartments

  • Use gentle fixation for membrane-associated forms

  • Consider live-cell imaging for secretory CLU trafficking studies

• Preservation of Post-translational Modifications:

  • Phosphatase inhibitors preserve phosphorylated forms

  • Proteasome inhibitors prevent degradation of nuclear CLU

What quantification methods are most reliable for CLU expression analysis in cancer tissues?

Reliable quantification of CLU expression in cancer tissues requires standardized approaches:

• IHC Scoring Systems:

  • H-score: Combines intensity (0-3) and percentage of positive cells (0-100%)

  • Allred score: Sum of proportion score (0-5) and intensity score (0-3)

  • Digital image analysis: Software-based quantification of staining intensity and distribution

• Multiplex Immunofluorescence:

  • Allows simultaneous detection of CLU with other markers

  • Enables cell type-specific quantification

  • Provides spatial context for expression patterns

• Tissue Microarray (TMA) Analysis:

  • Standardizes staining conditions across multiple samples

  • Permits high-throughput analysis

  • Reduces batch-to-batch variability

• Validation Through Multiple Approaches:

  • Correlate IHC with Western blot quantification

  • Compare protein levels with mRNA expression (qRT-PCR, RNA-seq)

  • Validate findings across independent cohorts

What are common issues with CLU antibodies and how can they be resolved?

Researchers frequently encounter several challenges when working with CLU antibodies:

• Inconsistent Molecular Weight Detection:

  • Issue: CLU appears at different molecular weights (37-80 kDa) in different systems .

  • Solution: Verify glycosylation status; use deglycosylating enzymes to confirm core protein size; validate using multiple antibodies against different epitopes.

• Non-specific Bands in Western Blot:

  • Issue: Additional bands appearing besides the expected CLU bands.

  • Solution: Optimize blocking conditions (5% BSA often works better than milk for glycoproteins); increase antibody dilution; validate with CLU-knockdown controls .

• Variable Subcellular Localization:

  • Issue: Discrepancies in nuclear vs. cytoplasmic staining .

  • Solution: Use antibodies specifically validated for subcellular localization; perform co-localization studies with organelle markers; compare results from multiple fixation methods.

• Background in IHC/IF:

  • Issue: High background obscuring specific staining.

  • Solution: Optimize blocking (extended blocking times); try different blocking agents (BSA, normal serum); increase washing steps; titrate primary and secondary antibodies.

• Loss of Antigenicity in Fixed Tissues:

  • Issue: Weak or absent staining in fixed tissues.

  • Solution: Compare different antigen retrieval methods (TE buffer pH 9.0 vs. citrate buffer pH 6.0) ; optimize retrieval time and temperature; consider alternative fixatives for prospective studies.

How can researchers ensure reproducibility in CLU antibody-based experiments?

Ensuring reproducibility requires systematic controls and standardized protocols:

• Antibody Validation and Documentation:

  • Document complete antibody information: source, catalog number, lot number, RRID

  • Include validation data: expected molecular weight, positive/negative controls

  • Maintain antibody validation records across experiments

• Standardized Protocols:

  • Develop detailed SOPs for each application (WB, IHC, IF)

  • Include all critical parameters: antibody dilutions, incubation times/temperatures, buffer compositions

  • Share protocols through repositories or supplementary materials

• Consistent Controls:

  • Include positive controls (known CLU-expressing tissues/cells)

  • Use negative controls (CLU siRNA-treated samples)

  • Implement isotype controls to assess non-specific binding

• Replication Strategy:

  • Perform technical replicates (same sample, multiple tests)

  • Include biological replicates (different samples from same condition)

  • Consider blind scoring for subjective assessments

• Quantification Standards:

  • Use calibrated standards for Western blot densitometry

  • Employ automated image analysis for IHC/IF quantification

  • Report statistical methods and significance thresholds

What considerations should researchers make when analyzing contradictory results from CLU antibody experiments?

When faced with contradictory results, researchers should systematically evaluate potential sources of variation:

• Antibody-Related Factors:

  • Epitope differences: Different antibodies target different regions of CLU

  • Clone specificity: Monoclonal vs. polyclonal antibodies recognize different epitopes

  • Batch-to-batch variation: Even same catalog antibodies may vary between lots

• Sample-Related Factors:

  • Tissue heterogeneity: CLU expression varies within different regions of the same tumor

  • Fixation artifacts: Overfixation or delayed fixation affects epitope availability

  • Post-translational modifications: Glycosylation patterns may differ between samples

• Methodological Approaches:

  • Resolution limitations: Some techniques cannot distinguish closely associated structures

  • Sensitivity thresholds: Different methods have different detection limits

  • Quantification methods: Subjective scoring vs. computational analysis

• Biological Reality:

  • True biological variation: CLU expression genuinely differs between patient subgroups

  • Disease stage effects: Expression patterns change during disease progression

  • Treatment effects: Prior treatments may alter CLU expression

For example, contradictory findings regarding CLU localization in lung cancer (nuclear vs. cytoplasmic) were attributed to potential sampling deviation, inadequate sample size, and value deviation in analysis methods . Researchers should consider multiple technical approaches and larger sample sizes to resolve such contradictions.

How are CLU antibodies being used to study the role of CLU in chemoresistance mechanisms?

CLU antibodies are instrumental in elucidating the complex role of CLU in chemoresistance:

• Expression Correlation Studies:

  • CLU antibodies enable quantification of CLU levels before and after chemotherapy

  • IHC and Western blot analyses reveal increased CLU expression in resistant tumors

  • Expression patterns correlate with clinical outcomes and treatment response

• Mechanistic Investigations:

  • Immunoprecipitation with CLU antibodies identifies binding partners in resistance pathways

  • Phospho-specific antibodies detect activation of downstream survival pathways

  • Co-localization studies reveal interactions with drug transporters or apoptotic machinery

• Therapeutic Monitoring:

  • Antibodies assess CLU downregulation efficacy after CLU-targeted therapies (e.g., Custirsen/OGX-011)

  • Sequential biopsies tracked with CLU antibodies show dynamic changes during treatment

  • Circulating CLU detection provides non-invasive monitoring options

• Predictive Biomarker Development:

  • Standardized IHC protocols using validated antibodies stratify patients by CLU expression

  • Multiple antibodies targeting different epitopes improve prediction accuracy

  • Combined analysis of CLU with other resistance markers enhances predictive power

Studies have demonstrated that high CLU expression confers resistance to chemotherapy and radiotherapy in lung cancer cell lines, and CLU silencing with Custirsen sensitizes cells to treatment while decreasing metastatic potential .

What are the latest advances in using CLU antibodies for cancer diagnostics and prognostics?

Recent advances in CLU antibody applications for cancer diagnostics and prognostics include:

• Multiplex Tissue Analysis:

  • Combined CLU with other cancer biomarkers in multiplex IHC panels

  • Single-cell analysis of CLU expression in tumor microenvironments

  • Spatial profiling of CLU in relation to immune infiltrates

• Liquid Biopsy Applications:

  • Detection of circulating CLU using sensitive immunoassays

  • Exosomal CLU analysis as minimally invasive biomarker

  • Correlation of plasma CLU levels with tumor burden and treatment response

• AI-Enhanced Image Analysis:

  • Machine learning algorithms for automated CLU staining interpretation

  • Pattern recognition to identify prognostic CLU distribution patterns

  • Integration of CLU expression with radiomics features

• Isoform-Specific Prognostics:

  • Differential prognostic value of nuclear versus cytoplasmic CLU

  • Antibodies specifically validated for distinguishing CLU isoforms

  • Correlation of specific isoforms with treatment outcomes

For NSCLC, cytoplasmic CLU staining is associated with longer survival in surgically resected patients, particularly in lung adenocarcinoma. CLU expression decreases from well-differentiated to poorly differentiated adenocarcinomas, suggesting its potential as a differentiation marker . The combination of proteomic studies and bioinformatic prediction has established CLU as a promising serological biomarker in lung adenocarcinoma .

How can researchers integrate CLU antibody data with other molecular profiling approaches?

Integrating CLU antibody data with other molecular profiling techniques creates comprehensive disease understanding:

• Multi-omics Integration Strategies:

  • Correlate CLU protein levels (antibody-based) with mRNA expression (RNA-seq/microarray)

  • Link CLU expression patterns to genomic alterations (mutations, CNVs)

  • Associate CLU with proteomic signatures and metabolic profiles

• Pathway Analysis Approaches:

  • Map CLU antibody data to known signaling pathways

  • Identify pathway co-activation patterns through simultaneous profiling

  • Validate computational predictions with antibody-based functional studies

• Single-cell Multi-parameter Analysis:

  • Combine CLU antibodies with other markers in CyTOF or imaging mass cytometry

  • Correlate CLU expression with cell type-specific markers

  • Track CLU expression changes during disease progression at single-cell resolution

• Clinical Data Integration:

  • Correlate CLU expression (antibody-based) with clinical outcomes

  • Develop integrated predictive models combining CLU with other biomarkers

  • Validate integrated signatures in independent patient cohorts

• Functional Validation:

  • Confirm predicted interactions using CLU antibodies in co-IP experiments

  • Validate regulatory relationships with ChIP-seq and CLU modulation studies

  • Use spatial transcriptomics to correlate CLU protein localization with local gene expression

In lung adenocarcinoma, researchers have successfully combined proteomic studies with bioinformatic prediction to establish CLU as part of a panel of serological biomarkers, alongside Calsyntenin-1 (CLSTN1) and neutrophil gelatinase-associated lipocalin (NGAL) .